by nikki mann | Sep 21, 2018 | News
This Symposium is an opportunity for scientists from academia and industry to discuss the latest academic and clinical research and how it could be applied in the pharma and biotech industry to develop new treatments. It is our key networking event for Milner... 
by nikki mann | Jun 21, 2018 | News
Computational Biology Programme Lead Namshik Han was on the panel at #Impact18 earlier this month, discussing how artificial intelligence is reshaping biotechnology and healthcare sectors. You can listen to Namshik’s ideas around AI in healthcare research,... 
by nikki mann | Jun 19, 2018 | News
SHIONOGI INVESTS IN NEMESIS TECHNOLOGY Japanese Pharma Company Joins £1.4M Seed Funding Round for Nemesis Bioscience Nemesis Bioscience today announced the completion of a Seed funding round of £1.4M from a syndicate of new investors including Shionogi & Co Ltd,... 
by nikki mann | Jun 18, 2018 | News
Scottish Enterprise will contribute up to £423,000 towards the industrial development of a novel antibody to treat autoimmune diseases Milner Affiliated company MedAnnex Ltd, an innovative biotechnology company developing new therapies to treat autoimmune diseases,... 
by nikki mann | May 4, 2018 | News
Registration for The Milner Therapeutics Symposium is now open! This Symposium is an opportunity for scientists from academia and industry to discuss the latest academic and clinical research and how it could be applied in the pharma and biotech industry to develop... 
by Nikki Mann | Apr 12, 2018 | News
Our new building is starting to take shape now, ready for the opening in October. The Milner Therapeutics Institute will have research laboratories within the Capella Building, which is on the Cambridge Biomedical Campus. The laboratories will house research groups...
